Nrx Pharmaceuticals, Inc. Announces FDA Declines Emergency Use Authorization for Zyesami® for Subgroup of Patients with Critical Covid-19 At Immediate Risk of Death from Respiratory Failure Despite Treatment with Approved Therapy, Including Remdesivir

NRx Pharmaceuticals, Inc. announced that the US Food and Drug Administration (FDA) has declined to issue an Emergency Use Authorization (EUA) for ZYESAMI® (aviptadil) for a sub-group of patients that in addition to ZYESAMI®, also received Remdesivir and continued to progress.  NRx Pharmaceuticals had submitted this last EUA application using data from a post-hoc subgroup analysis.